Expression of insulin-like growth factor-II transcripts in Wilms' tumour

Nature. 1985 Sep 19-25;317(6034):258-60. doi: 10.1038/317258a0.


Wilms' tumour probably arises from embryonal kidney cells and occurs in both hereditary and sporadic forms. Knudson and Strong have suggested that both forms of the disease are initiated by two mutational events. In the case of the inherited form, cytogenetic evidence indicates that a germline deletion of chromosome band 11p13 may correspond to one of the two mutations. DNA mapping evidence is consistent with the notion that the tumour susceptibility gene (Wg) on chromosome 11 is actually recessive. Comings has proposed that the dominantly inherited tumours may arise by the inactivation or loss of a diploid pair of regulatory genes which normally suppress the expression of a structural transforming gene (Tg). It has recently been suggested that the N-myc oncogene may serve as a transforming gene in retinoblastoma, although no such gene has yet been identified in Wilms' tumour. We now report that in four cases of Wilms' tumour, insulin-like growth factor-II (IGF-II) transcripts are highly elevated compared with the adjacent normal kidney. In addition, we have mapped the gene for IGF-II to chromosome band 11p14.1, which is in the immediate vicinity of Wg. These findings suggest that IGF-II may be involved in the aetiology of Wilms' tumour.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Cycle / drug effects
  • Chromosome Banding
  • Chromosomes, Human, 6-12 and X
  • Female
  • Genes*
  • Humans
  • Insulin-Like Growth Factor II / genetics*
  • Kidney / metabolism
  • Kidney Neoplasms / genetics*
  • Kidney Neoplasms / pathology
  • Methotrexate / pharmacology
  • Mitosis
  • Nucleic Acid Hybridization
  • Oncogenes
  • Placenta / metabolism
  • Plasmids
  • Pregnancy
  • Protein Biosynthesis*
  • Somatomedins / genetics*
  • Transcription, Genetic*
  • Wilms Tumor / genetics*
  • Wilms Tumor / pathology


  • Somatomedins
  • Insulin-Like Growth Factor II
  • Methotrexate